fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Methimazole

All products: general benefit

Tapazole · DIN 00015741 · 5 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-16 — choose a marketed DIN from the same-category list.Discontinued July 16, 2026 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-16 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-16 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Tapazole · DIN 00015741 Manufacturer: Knight Therapeutics Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2026-07-16 · brand TAPAZOLE · ATC H03BB02 THIAMAZOLE · form Tablet · route Oral · ingredients METHIMAZOLE 5 MG · company Knight therapeutics inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $0.1531 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00015741)

Source record
DIN 00015741: Tapazole Raw flags: sec3=Y Item: 683800001; group id 808; item number 1985; lccId None; manufacturer id KNT Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.3696; ministry $0.1531 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00015741 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9
Interchangeable products
Jamp Methimazole · DIN 02490625 · $0.1531 Mar-Methimazole · DIN 02480107 · $0.1531
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since July 16, 2026 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:38 Anti-Thyroids) and how they are covered
No products matched this class search: “68:38”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MAR-METHIMAZOLE is indicated in adults for: • The medical treatment of hyperthyroidism. Long-term therapy may lead to remission of the disease. • Amelioration of hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy. • Use when thyroidectomy is contraindicated or not advisable. 1.1. Pediatrics Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (≥ 65 years): Clinical studies did not include sufficient numbers of subjects aged 65 years or older to determine the safety and efficacy of methimazole in this geriatric population (see 4.2 Recommended Dose and Dosage Adjustment and 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00072961.PDF PM date: October 10, 2023 Source product: MAR-METHIMAZOLE; DIN 02480107; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.